Rocbrutinib clinical trials
Rocbrutinib is named as an intervention in 11 current clinical trials in our China and USA registers. 9 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Guangzhou Lupeng Pharmaceutical Company LTD (9). The most-studied condition is Diffuse Large B-Cell Lymphoma (DLBCL). The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Rocbrutinib works
All drug targets →- B-cell chronic lymphocytic leukemiaPhase 3
- Mantle cell lymphomaPhase 3
- Diffuse large B-cell lymphomaPhase 2
- Waldenstrom macroglobulinemiaPhase 1
- Follicular lymphomaPhase 1
- Hairy cell leukemiaPhase 1
- Marginal zone lymphomaPhase 1
- Non-Hodgkin lymphomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314539, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12875, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Rocbrutinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Rocbrutinib
- ChEMBL
- CHEMBL5314539
- DrugBank
- DB19445
- PubChem CID
- 139416847
- CAS number
- 2485861-07-0
- FDA UNII
- KD68L3GRW2
- Wikidata
- Q140641595
- Wikipedia
- Rocbrutinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Rocbrutinib
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Rocbrutinib in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Rocbrutinib. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects
2026-525656-28-00 · CTIS ↗ · Hemic and Lymphatic Diseases
|
Phase 3 | Authorised | Newave Pharmaceutical Inc | Poland, Germany, Spain + 3 more |
Conditions studied with Rocbrutinib
18 conditionsAll 18 conditions
| Condition (as registered) | Trials |
|---|---|
| Diffuse Large B-Cell Lymphoma (DLBCL) | 2 |
| Mantle Cell Lymphoma (MCL) | 2 |
| CLL / SLL | 1 |
| CLL (Chronic Lymphocytic Leukemia) | 1 |
| CLL, Refractory | 1 |
| CLL, Relapsed | 1 |
| Relapsing-remitting Multiple Sclerosis (RRMS) | 1 |
| Mantle Cell Lymphoma | 1 |
| B-cell Non-Hodgkin Lymphoma | 1 |
| Clinical Pharmacology | 1 |
| Follicular Lymphoma ( FL) | 1 |
| Waldenström Macroglobulinemia (WM) | 1 |
| DLBCL | 1 |
| CLL/SLL | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Follicular Lymphoma | 1 |
| Diffuse Large B Cell Lymphoma | 1 |
| B-cell Lymphoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Guangzhou Lupeng Pharmaceutical Company LTD | 9 |
| Newave Pharmaceutical Inc | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 7 |
| Clinical trials in USA | 2 | 2 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Rocbrutinib trials
How many clinical trials are testing Rocbrutinib?
11 current trials in our China and USA registers name Rocbrutinib (also registered as LP-168) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Rocbrutinib trials recruiting patients?
Yes. 9 of the 11 trials are recruiting: 7 with sites in China and 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rocbrutinib clinical trials?
Guangzhou Lupeng Pharmaceutical Company LTD (9) and Newave Pharmaceutical Inc (2). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rocbrutinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rocbrutinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rocbrutinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.